Launch low testosterone and menopausal support solutions on the platform
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 May 2025
- Due
- 31 Dec 2025
- Delivered
- by 10 Sep 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Lab testing capabilities pave the way to launch more extensive low testosterone and menopausal support solutions expected on our platform by year-end”
What we found
Evidence strength B What the grades mean
Hims launched low testosterone support in September 2025 and menopausal support by end of 2025, meeting the year-end deadline.
-
B Hers Launches Menopause and Perimenopause Specialty
“Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women's health, offering access to affordable treatment plans built specifically for women experiencing perimenopause and menopause.” ✓ confirmed on the page
-
B Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
“Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new category in men's health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.” ✓ confirmed on the page
-
D Hims & Hers Fourth Quarter 2025 Earnings Call Transcript
“Within a span of three months in 2025, we launched our new labs offering as well as hormone therapies with support for low testosterone, menopause and perimenopause.”
Checked 8 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Low testosterone and menopausal support solutions
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Hims & Hers Health, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-HIMS-003642 · Corrections policy